

RECEIVED

2005 JUL -6 A 11:07

OFFICE OF INTERNATIONAL  
CORPORATE FINANCE

Norwood Abbey Ltd ACN 085 162 456 ABN 20 085 162 456  
63 Wells Road Chelsea Heights Victoria 3196 Australia

Telephone 9782 7333  
Facsimile 9782 7334  
norwood@norwoodabbey.com.au



05009473

4 July 2005

Office of International Corporate Finance  
Securities and Exchange Commission  
Stop 3-2  
450 Fifth Street, N.W.  
Washington, D.C. 20549

SUPPL

Re: Norwood Abbey Ltd. (the "Issuer")  
File Number 82-34754

To Whom it May Concern:

PROCESSED

I enclose for submission the following reports as filed in Australia:

JUL 06 2005

Date of Issue	Subject
04/7/05	Norwood Immunology Clinical Trials Progress
30/6/05	Results of Extraordinary General Meeting
21/6/05	Needle-free Device Successfully Delivers Chemical Mulesing Protein in Live Sheep Trial

THOMSON  
FINANCIAL

The information is being submitted to the Securities and Exchange Commission with respect to the Issuer's obligations pursuant to Rule 12g3-2(b), and with the understanding that, in accordance with the terms of paragraph (b)(4) of Rule 12g3-2(b), such information and documents will not be deemed "filed" with the Commission, or otherwise subject to the liabilities of Section 18 of the Exchange Act. Kindly acknowledge receipt of the enclosed by stamping and returning the enclosed copy of this letter in the pre-addressed, stamped envelope provided for your convenience.

Yours faithfully

Lula Liossi  
Corporate Communications Manager  
Norwood Abbey Ltd

dlw 7/6

Lippert/Heilshorn & Associates, Inc.  
Kim Sutton Golodetz (kgolodetz@lhai.com)  
212-838-3777  
Bruce Voss (bvoss@lhai.com)  
310-691-7100  
Chenoa Taitt (ctaitt@lhai.com)  
212-838-3777  
www.lhai.com

30 June 2005

By Facsimile: 1300 300 021

Manager Companies  
Company Announcements Office  
Australian Stock Exchange Limited  
Level 4, Stock Exchange Centre  
20 Bridge Street  
SYDNEY NSW 2000

Dear Sir/Madam

**Results of Extraordinary General Meeting  
NORWOOD ABBEY LIMITED**

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise that the Extraordinary General Meeting of Norwood Abbey Limited was held today.

Details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

Yours faithfully

**Jeffrey Bell**  
Company Secretary

**NORWOOD ABBEY LIMITED**  
**Extraordinary General Meeting**

**Proxy Summary**  
**30 June 2005**

**1 Ratification of prior issues of securities**

Proxy votes exercisable by all validly appointed proxies were to be exercised as follows:

<b>In Favour</b>	<b>Against</b>	<b>Abstention</b>	<b>Proxy's discretion</b>
55,901,703	528,169	17,203,909	712,046

The motion was carried on a show of hands as an ordinary resolution.

**2 Approval of issue of securities**

Proxy votes exercisable by all validly appointed proxies were to be exercised as follows:

<b>In Favour</b>	<b>Against</b>	<b>Abstention</b>	<b>Proxy's discretion</b>
61,947,733	3,940,169	17,205,609	712,046

The motion was carried on a show of hands as an ordinary resolution.

**3 Issue of Options to non-executive Director Professor Ian Hunter**

Proxy votes exercisable by all validly appointed proxies were to be exercised as follows:

<b>In Favour</b>	<b>Against</b>	<b>Abstention</b>	<b>Proxy's discretion</b>
60,282,819	4,864,193	17,946,499	712,046

The motion was carried on a show of hands as an ordinary resolution.


## NORWOOD IMMUNOLOGY CLINICAL TRIALS PROGRESS

### Key points:

- Autologous bone marrow transplant (BMT) trial approved by FDA, obtains IRB approval from MD Anderson & nearing IRB approval from Dana-Farber
- Investigators' protocol implementation meeting mid-July
- Clinical Trial Agreement being finalised
- Trial co-funded by NIH consortium (Dana-Farber as Grantee), with support from TAP Pharmaceutical Products Inc. and NIM
- Immune function study (LIMS) protocol nearing IRB approvals from University of California & Georgetown University
- LIMS study to be funded by TAP

Medical technologies group Norwood Abbey Ltd [ASX:NAL] advises that its subsidiary Norwood Immunology Ltd [AIM: NIM] has made substantial progress in its clinical trials program. Both the autologous bone marrow transplant (BMT) trial and the immune function study (LIMS) are on track for enrolment of first patients during the third quarter of calendar 2005.

The processes in planning, designing, obtaining relevant approvals and implementation are complex, require significant skilled resources and are time consuming. The diagram below, describing the BMT study planning process, is designed to illustrate to shareholders the many steps involved and also to highlight that the BMT trial is close to a start date.





For further information on Norwood Immunology visit [www.norwoodimmunology.com](http://www.norwoodimmunology.com)

**For further information contact:**

Richard Williams  
Chief Executive Officer  
Norwood Immunology Limited  
+44 (0) 7860 295153

Bernie Romanin  
Snr. VP – Corporate Development  
Norwood Abbey Limited  
+61-3-9782-7333

Michael Kotowicz  
RADAR Investor Relations  
+61-2-8256-3333

U.S. Investor and Media Contacts:  
Lippert/Heilshorn & Associates, Inc.  
Kim Sutton Golodetz ([kgolodetz@lhai.com](mailto:kgolodetz@lhai.com))  
212-838-3777  
Bruce Voss ([bvoss@lhai.com](mailto:bvoss@lhai.com))  
310-691-7100  
Chenoa Taitt ([ctaitt@lhai.com](mailto:ctaitt@lhai.com))  
212-838-3777  
[www.lhai.com](http://www.lhai.com)

**Background:**

Norwood Immunology has licensed its immunology intellectual property to TAP for commercialization in the United States, utilizing TAP's GnRH analogue, Lupron Depot® (leuprolide acetate for depot suspension). This combined initiative is exploring the use of Lupron Depot in regenerating the thymus gland and in turn "re-booting" the body's immune system, enabling patients to better recover from life-threatening diseases.

TAP Pharmaceutical Products Inc., located in Lake Forest, IL., U.S.A., is a joint venture between Abbott, headquartered in Abbott Park, IL., U.S.A., and Takeda Pharmaceutical Company Limited of Osaka, Japan. TAP currently markets Lupron Depot and Prevacid® (lansoprazole). For more information about TAP and its products, please visit the company's web site at [www.tap.com](http://www.tap.com)